Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMPH stock price vs PD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PD's multiple
Needs PD P/E.
Implied fair value · at AMPH's multiple
Needs AMPH P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMPH FY 2025 (ended Dec 31, 2025) · PD FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 61% equity / 39% debt · EV / Revenue 1.84x · EV / EBITDA 6.20x
Capital structure 72% equity / 28% debt · EV / Revenue 2.08x · EV / EBITDA 25.43x
AMPH carries the larger enterprise value at $1.32B against $1.02B; AMPH trades on the lower EV / Revenue multiple (1.84x vs 2.08x); AMPH on the lower EV / EBITDA (6.20x vs 25.43x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amphastar Pharmaceuticals, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
PAGERDUTY, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.79x
1.66x
Net debt / EBITDA
Leverage against operating earnings
1.58x
-1.22x
Cash and equivalents
Liquid reserves on the balance sheet
$282.81M
$469.84M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BRISTOL MYERS SQUIBB CO
AMPH vs BMY
TEVA PHARMACEUTICAL INDUSTRIES LTD
AMPH vs TEVA
Bausch Health Companies Inc.
AMPH vs BHC
PERRIGO Co plc
AMPH vs PRGO
ANI PHARMACEUTICALS INC
AMPH vs ANIP
Atlassian Corp
AMPH vs TEAM
Gitlab Inc.
AMPH vs GTLB
Elastic N.V.
AMPH vs ESTC
Dynatrace, Inc.
AMPH vs DT
ServiceNow, Inc.
AMPH vs NOW
$619.71M
$420.61M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
